Trials / Completed
CompletedNCT05197062
A Study of 14C JNJ-67953964 in Healthy Adult Male Participants
A Phase 1, Open Label Study to Characterize the Absorption, Metabolism, and Excretion of 14C JNJ-67953964 After a Single Dose in Healthy Adult Male Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- Male
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess the pharmacokinetic (PK), metabolism, and routes of excretion of aticaprant and its metabolites in excreta and in plasma after a single oral dose 14C-aticaprant in healthy adult male participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 14C-aticaprant | 14C-aticaprant will be administered orally as capsule on Day 1. |
Timeline
- Start date
- 2022-01-14
- Primary completion
- 2022-03-02
- Completion
- 2022-03-02
- First posted
- 2022-01-19
- Last updated
- 2025-04-27
Locations
1 site across 1 country: Netherlands
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05197062. Inclusion in this directory is not an endorsement.